MedWatch

New Zealand CEO to open the door to the US - chairman has three demands

The new CEO of Zealand Pharma was appointed due to his experience with launching products in the US - a market the Danish company is about to enter. And chairman Martin Nicklasson has more tasks for the new executive.

Emmanuel Dulac takes position in Zealand Pharma as of April 22. | Foto: Zealand Pharma

Danish Zealand Pharma has appointed Emmanuel Dulac from US-based Alnylam as new CEO. Although the job change entails a move across the Atlantic, Dulac will most likely continue to spend much time in the US - a market Zealand Pharma is preparing to enter.

Much of Dulac's work for Zealand Pharma will thus take place in the US, says chairman of the board Martin Nicklasson, who has three main tasks for the new CEO: to ensure deals and approvals in the US, to prepare Zealand's phase III candidates for production and to enter deals and partnerships about the company's early-stage projects.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Coloplasts nye skattedetaljer viser enorme nationale forskelle - Danmark blandt de laveste skatteopkrævere

Mens Coloplast betaler godt 20 pct. i effektiv skattesats herhjemme, lægger medicoselskabet næsten 40 pct. i skatteposen af sit overskud i Frankrig, viser nye detaljerede skatteoplysninger fra virksomheden. Størstedelen af medicoselskabets ansatte arbejder i Ungarn, hvor firmaet også betaler den laveste selskabsskat på bare 15 pct, men produktionen er lagt i landet af en række andre årsager, fortæller Coloplast.

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier